Jan Delabie

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/11071/jan-delabie-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

237	28,162	70	167
papers	citations	h-index	g-index
242 ext. papers	31,814 ext. citations	6.3 avg, IF	5.72 L-index

#	Paper	IF	Citations
237	Concurrent Primary Follicular Lymphoma and a Mature Cystic Teratoma of the Ovary: A Case Report and Review of Literature <i>Case Reports in Pathology</i> , 2022 , 2022, 5896696	0.9	
236	Integrating whole genome sequencing, methylation, gene expression, topological associated domain information in regulatory mutation prediction: A study of follicular lymphoma <i>Computational and Structural Biotechnology Journal</i> , 2022 , 20, 1726-1742	6.8	
235	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. <i>Blood</i> , 2021 , 138, 132	62.12326	50
234	DNA Methylation-Based Classification of Small B-Cell Lymphomas: A Proof-of-Principle Study. Journal of Molecular Diagnostics, 2021 , 23, 1774-1786	5.1	
233	Breast implant-associated EBV-positive diffuse large B-cell lymphoma: Two case reports and literature review. <i>Pathology Research and Practice</i> , 2021 , 226, 153589	3.4	1
232	The Mutational Landscape of Cold Agglutinin Disease. <i>Blood</i> , 2020 , 136, 14-15	2.2	
231	Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18. <i>Blood Advances</i> , 2020 , 4, 993-996	7.8	6
230	BayesPI-BAR2: A New Python Package for Predicting Functional Non-coding Mutations in Cancer Patient Cohorts. <i>Frontiers in Genetics</i> , 2019 , 10, 282	4.5	3
229	Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. <i>Blood</i> , 2019 , 134, 19-19	2.2	3
228	Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 2027-2027	2.2	
227	Cold Agglutinin Disease Shows Highly Recurrent Gains of Chromosome 3, 12 and 18. <i>Blood</i> , 2019 , 134, 1488-1488	2.2	O
226	and hijack immunoglobulin light-chain enhancers in cyclin D1 mantle cell lymphoma. <i>Blood</i> , 2019 , 133, 940-951	2.2	48
225	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1396-1407	59.2	780
224	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018 , 560, 387-391	50.4	172
223	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018 , 132, 2401-2405	2.2	39
222	CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. <i>Blood Advances</i> , 2018 , 2, 3506-3514	7.8	9
221	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018 , 132, 413-422	2.2	58

(2015-2017)

220	Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2017 , 102, e195-e198	6.6	16	
219	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. <i>Blood</i> , 2017 , 129, 759-770	2.2	52	
218	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 428-435	4.7	40	
217	Folliculotropic Mycosis Fungoides with Skewed T-cell Receptor CDR3 Motif: Suggestive of Lipid-antigen Selection?. <i>Acta Dermato-Venereologica</i> , 2017 , 97, 1081-1086	2.2	2	
216	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1668-1677	2.2	67	
215	Integrative whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma. <i>Scientific Reports</i> , 2017 , 7, 7040	4.9	12	
214	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. <i>Blood</i> , 2017 , 130, 1819-1831	2.2	42	
213	MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2017 , 7, 654	7	17	
212	Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 623-632	1.9	5	
211	Primary Cutaneous Follicular Helper T-cell Lymphoma in a Patient With Neurofibromatosis Type 1: Case Report and Review of the Literature. <i>American Journal of Dermatopathology</i> , 2017 , 39, 134-139	0.9	1	
210	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , 2016 , 57, 717-20	1.9	11	
209	The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2016 , 175, 102-14	4.5	46	
208	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2016 , 29, 494-507	24.3	72	
207	Localized lymphoid hyperplasia of the spleen: a rare benign condition grossly mimicking malignancy. <i>Journal of Hematopathology</i> , 2016 , 9, 85-89	0.4	2	
206	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. <i>British Journal of Haematology</i> , 2016 , 175, 410-418	4.5	118	
205	Primary Marginal Zone Lymphoma of the Subcutis Associated With Panniculitis and Fat Necrosis. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 341-6	1.9	3	
204	Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature. <i>American Journal of Clinical Pathology</i> , 2015 , 143, 797-806	1.9	22	
203	Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2598-607	1.9	21	

202	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 13447-54	11.5	105
201	Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. <i>Haematologica</i> , 2015 , 100, 238-45	6.6	62
200	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1742-9	1.9	9
199	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. <i>Blood</i> , 2015 , 125, 1137-45	2.2	87
198	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. <i>Blood</i> , 2015 , 125, 2669-77	2.2	37
197	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. <i>Blood</i> , 2015 , 125, 82-9	2.2	37
196	Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell. <i>Haematologica</i> , 2015 , 100, e415-8	6.6	3
195	Comprehensive genome-wide transcription factor analysis reveals that a combination of high affinity and low affinity DNA binding is needed for human gene regulation. <i>BMC Genomics</i> , 2015 , 16 Suppl 7, S12	4.5	15
194	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 1322-30	6.7	45
193	Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma. <i>Histopathology</i> , 2015 , 67, 62-9	7.3	11
192	Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. <i>PLoS ONE</i> , 2015 , 10, e0131158	3.7	18
191	The first report of a previously undescribed EBV-negative NK-cell lymphoma of the GI tract presenting as chronic diarrhoea with eosinophilia. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	4
190	Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. <i>Cancer Discovery</i> , 2014 , 4, 480-93	24.4	100
189	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014 , 45, 2144-53	3.7	30
188	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014 , 123, 1214-7	2.2	404
187	Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma. <i>PLoS ONE</i> , 2014 , 9, e91031	3.7	17
186	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , 2014 , 123, 1681-90	2.2	87
185	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014 , 123, 2915-23	2.2	299

(2014-2014)

184	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. <i>Blood</i> , 2014 , 123, 2953-9	2.2	77
183	Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. <i>Haematologica</i> , 2014 , 99, 497-504	6.6	83
182	A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma. <i>PLoS ONE</i> , 2014 , 9, e104249	3.7	10
181	Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. <i>Blood</i> , 2014 , 123, 1051-4	2.2	37
180	Loss of signalling via G#3 in germinal centre B-cell-derived lymphoma. <i>Nature</i> , 2014 , 516, 254-8	50.4	192
179	SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphomaa Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2014 , 166, 98-108	4.5	98
178	Personalized lymphoma diagnosis and treatment: recent advances. <i>Diagnostic Histopathology</i> , 2014 , 20, 431-439	0.7	
177	Multiple distinct T-cell clones in folliculotropic mycosis fungoides. <i>American Journal of Dermatopathology</i> , 2014 , 36, 972-6	0.9	3
176	Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma. <i>Epigenetics</i> , 2014 , 9, 428-36	5.7	27
175	Non-MALT Marginal Zone Lymphoma 2014 , 241-251		
174	Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. <i>Blood</i> , 2014 , 124, 3016-3016	2.2	1
173	A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. <i>Blood</i> , 2014 , 124, 3094-3094	2.2	2
172	Primary Mediastinal Large B-Cell Lymphoma 2014 , 195-206		1
171	Characterization of the Microrna Expression Profiles of Paired Primary and Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) By Next-Generation Sequencing. <i>Blood</i> , 2014 , 124, 1626-1626	2.2	
170	Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials. <i>Blood</i> , 2014 , 124, 2994-2994	2.2	
169	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. <i>Blood</i> , 2014 , 124, 1667-1667	2.2	
168	Principles of the Pathology and Biology of Malignant Lymphomas 2014 , 3-16		
167	Cutaneous T-Cell Lymphoma 2014 , 133-167		

Nodular Lymphocyte-Predominant Hodgkin Lymphoma **2014**, 343-352

165	Anaplastic Large Cell Lymphoma 2014, 111-120		
164	Waldenstr⊞ Macroglobulinemia 2014 , 303-329		
163	Mucosal-Associated Lymphoid Tissue (MALT) Lymphoma 2014 , 253-276		
162	Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4520-8	2.2	93
161	High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. <i>Blood</i> , 2013 , 121, 1367-76	2.2	131
160	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. <i>International Journal of Cancer</i> , 2013 , 133, 2852-63	7.5	11
159	Malignant phyllodes tumor and acute megakaryoblastic leukemia sharing a common clonal origin. <i>Case Reports in Hematology</i> , 2013 , 2013, 934781	0.7	
158	Clinical and histopathological features of folliculotropic mycosis fungoides: a Norwegian patient series. <i>Acta Dermato-Venereologica</i> , 2013 , 93, 325-9	2.2	34
157	Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3943-8	11.5	44
156	CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma. ISRN Oncology, 2013, 2013, 252318		22
155	Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. <i>European Journal of Haematology</i> , 2013 , 91, 332-8	3.8	8
154	Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. <i>American Journal of Clinical Pathology</i> , 2013 , 139, 242-54	1.9	27
153	Bone marrow histology in monoclonal B-cell lymphocytosis shows various B-cell infiltration patterns. <i>American Journal of Clinical Pathology</i> , 2013 , 139, 390-5	1.9	17
152	Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. <i>Blood</i> , 2013 , 122, 3599-606	2.2	124
151	Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma. <i>PLoS ONE</i> , 2013 , 8, e79602	3.7	10
150	Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM. <i>Blood</i> , 2013 , 122, 1768-1768	2.2	2
149	Global Profiling Of Outcome Associated Alternative Splicing Events and Gene Expression In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013 , 122, 75-75	2.2	

148	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue [An L.L.M.P.P. Project. <i>Blood</i> , 2013 , 122, 73-73	2.2	
147	Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort. <i>Blood</i> , 2013 , 122, 4272-4272	2.2	
146	Primary Cold Agglutinin Associated Lymphoproliferative Disease: A B-Cell Lymphoma Of The Bone Marrow Distinct From Lymphoplasmacytic Lymphoma. <i>Blood</i> , 2013 , 122, 4335-4335	2.2	
145	Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. <i>British Journal of Haematology</i> , 2012 , 158, 355-62	4.5	198
144	Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEACI-Gutologous stem-cell support: still very long survival but late relapses do occur.	4.5	1
143	British Journal of Haematology, 2012 , 158, 815-816 Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. <i>Blood</i> , 2012 , 119, 3757-66	2.2	56
142	Keeping good and bad company: stromal cells in lymphoma. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1654-5	1.9	
141	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012 , 120, 2290-6	2.2	48
140	Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma. <i>BMC Cancer</i> , 2012 , 12, 478	4.8	15
139	Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients. <i>British Journal of Haematology</i> , 2012 , 159, 604-8	4.5	5
138	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012 , 490, 116-20	50.4	600
137	Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. <i>Blood</i> , 2012 , 119, 4939-48	2.2	79
136	Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. <i>British Journal of Haematology</i> , 2012 , 156, 225-33	4.5	90
135	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3452-9	2.2	669
134	Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3093-9	2.2	362
133	In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. <i>Haematologica</i> , 2012 , 97, 270-8	6.6	121
132	Alternative Splicing and Expression of Class II Tubulin Beta (TUBB2B) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012 , 120, 1557-1557	2.2	1
131	Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2012 , 120, 679-679	2.2	2

130	Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients Blood, 2012 , 120, 747-747	2.2	2
129	Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma <i>Journal of Clinical Oncology</i> , 2012 , 30, 8074	- 807 4	
128	Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma <i>Blood</i> , 2012 , 120, 2648-2648	2.2	
127	Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity. <i>Blood</i> , 2011 , 118, 3331-9	2.2	41
126	Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. <i>Blood</i> , 2011 , 118, 148-55	2.2	254
125	MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. <i>Blood</i> , 2011 , 118, 5550-8	2.2	63
124	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011 , 96, 996-1001	6.6	75
123	High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. <i>British Journal of Haematology</i> , 2011 , 152, 600-10	4.5	40
122	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011 , 470, 115-9	50.4	1068
121	Mantle cell lymphoma with features of marginal-zone lymphoma. <i>Journal of Hematopathology</i> , 2011 , 4, 7-11	0.4	3
120	Diffuse large B-cell lymphoma cycling off the main track. <i>Leukemia and Lymphoma</i> , 2011 , 52, 358-9	1.9	
119	Richter syndrome presenting as a solitary cerebellar tumor during first-line treatment for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2007-9	1.9	4
118	The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. <i>American Journal of Clinical Pathology</i> , 2011 , 135, 54-61	1.9	60
117	Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. <i>Journal of Clinical Oncology</i> , 2011 , 29, 200-7	2.2	360
116	Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. <i>Clinical Cancer Research</i> , 2011 , 17, 3727-32	12.9	60
115	BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. <i>Clinical Cancer Research</i> , 2011 , 17, 7785-95	12.9	132
114	High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01). <i>Blood</i> , 2011 , 118, 331-331	2.2	3
113	Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab. <i>Blood</i> , 2011 , 118, 1641-1641	2.2	

112	Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. <i>Blood</i> , 2011 , 118, 435-435	2.2	
111	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010 , 463, 88-92	50.4	1149
110	IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 1686-94	6.7	212
109	T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. <i>Haematologica</i> , 2010 , 95, 440-8	6.6	48
108	Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , 2010 , 362, 875-85	59.2	961
107	Prognostic markers in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1588-9	1.9	1
106	Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type. <i>Haematologica</i> , 2010 , 95, 133	4 ⁶ 49	11
105	ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. <i>Haematologica</i> , 2010 , 95, 509-13	6.6	78
104	Malignant lymphoma of the tongue with unusual cytology in a pleural effusion: a case report. <i>Acta Cytologica</i> , 2010 , 54, 645-8	3	O
103	Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2010 , 115, 1026-36	2.2	289
102	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). <i>Blood</i> , 2010 , 115, 1530-3	2.2	143
101	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. <i>Blood</i> , 2010 , 116, 953-61	2.2	105
100	Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. <i>Blood</i> , 2010 , 116, 1489-97	2.2	49
99	Cooperative epigenetic modulation by cancer amplicon genes. <i>Cancer Cell</i> , 2010 , 18, 590-605	24.3	230
98	Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (. <i>American Journal of Hematology</i> , 2010 , 85, 261-3	7.1	6
97	R-CHOEP-14 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2B: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18B5 Years <i>Blood</i> , 2010 , 116, 2805-2805	2.2	2
96	Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01). <i>Blood</i> , 2010 , 116, 3565-3565	2.2	4
95	Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01). <i>Blood</i> , 2010 , 116, 3566-3566	2.2	5

94	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2010 , 116, 2005-2005	2.2	
93	Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group	2.2	
92	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica</i> , 2009 , 94, 1555-62	6.6	299
91	Transformation of B cell lymphoma to histiocytic sarcoma: somatic mutations of PAX-5 gene with loss of expression cannot explain transdifferentiation. <i>Journal of Hematopathology</i> , 2009 , 2, 135-41	0.4	21
90	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. <i>Blood</i> , 2009 , 114, 826-34	2.2	136
89	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1875-8	1.9	9
88	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. <i>Clinical Cancer Research</i> , 2009 , 15, 5494-502	12.9	507
87	CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica, 2009 , 94, 596-8	6.6	18
86	NK-Cell Lymphoma Shares Strikingly Similar Molecular Features with a Distinct Set of T -Cell Lymphoma and Identification of Aurora Kinase A Inhibitor as a Novel Therapeutic Agent <i>Blood</i> , 2009 , 114, 313-313	2.2	
85	Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project <i>Blood</i> , 2009 , 114, 620-620	2.2	
84	Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL) <i>Blood</i> , 2009 , 114, 2922-2922	2.2	
83	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT) <i>Blood</i> , 2009 , 114, 1948-1948	2.2	
82	Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. <i>Science</i> , 2008 , 319, 1676-9	33.3	660
81	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13520-5	11.5	746
8o	Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. <i>Haematologica</i> , 2008 , 93, 1327-34	6.6	72
79	Concurrent mediastinal germ-cell tumour and haematological malignancy: case report and short review of literature. <i>Acta Oncolgica</i> , 2008 , 47, 466-9	3.2	16
78	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008 , 112, 3088-98	2.2	138
77	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. <i>Blood</i> , 2008 , 112, 2687-93	2.2	472

76	NOTCH2 mutations in marginal zone lymphoma. <i>Haematologica</i> , 2008 , 93, 1107-9	6.6	46
75	Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008 , 453, 407-11	5.1	21
74	Loss of CIITA and MHC Class II Expression in Diffuse Large B-Cell Lymphoma Is Not Explained by Methylation of CIITA Promoters III and IV <i>Blood</i> , 2008 , 112, 1786-1786	2.2	
73	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2008 , 112, 475-475	2.2	
72	Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma <i>Blood</i> , 2008 , 112, 2049-2049	2.2	
71	Molecular Signatures to Improve Diagnosis, Prognostication and Identification of Oncogenic Pathways in Peripheral T and NK Cell Lymphoma <i>Blood</i> , 2008 , 112, 3339-3339	2.2	
70	R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2B: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years. <i>Blood</i> ,	2.2	
69	2008 , 112, 3604-3604 Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007 , 46, 1090-7	5	32
68	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. <i>British Journal of Haematology</i> , 2007 , 136, 286-93	4.5	124
67	Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007 , 450, 559-65	5.1	9
66	Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1216-22	2.2	148
65	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007 , 109, 4599-606	2.2	183
64	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2007 , 110, 4396-405	2.2	83
63	Granulomatous slack skin with a translocation t(3;9)(q12;p24). <i>American Journal of Surgical Pathology</i> , 2007 , 31, 803-6	6.7	12
62	Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy <i>Blood</i> , 2007 , 110, 348-348	2.2	6
61	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma <i>Blood</i> , 2007 , 110, 692-692	2.2	2
60	Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH <i>Blood</i> , 2007 , 110, 2631-2631	2.2	
59	Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study <i>Blood</i> , 2007 , 110, LB1-LB	1 ^{2.2}	

58	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations <i>Blood</i> , 2007 , 110, 360-360	2.2	1
57	Molecular cytogenetic analysis of leukemic mantle cell lymphoma with a cryptic t(11;14). <i>Cancer Genetics and Cytogenetics</i> , 2006 , 165, 172-5		5
56	BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 961-8	2.2	238
55	Molecular diagnosis of Burkitt's lymphoma. <i>New England Journal of Medicine</i> , 2006 , 354, 2431-42	59.2	700
54	Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 2352-7	11.5	116
53	The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. <i>Journal of Pathology</i> , 2006 , 208, 431-8	9.4	30
52	Peripheral T-cell lymphoma with involvement of the expanded mantle zone. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 449, 78-87	5.1	33
51	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. <i>Blood</i> , 2006 , 107, 1101-7	2.2	60
50	Testicular Diffuse Large B-Cell Lymphoma of Activated B-Cel Subtype Is Frequently Associated with Clonally Related Non-Follicular Small B-Cell Lymphoma in the Bone Marrow <i>Blood</i> , 2006 , 108, 2042-204	1 <mark>2</mark> .2	1
49	VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information <i>Blood</i> , 2006 , 108, 2421-2421	2.2	
48	Structural Profiles of p53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study <i>Blood</i> , 2006 , 108, 811-811	2.2	
47	Intensifying Methotrexate (MTX) Dosage Reduces Treatment Failure in Adults with Burkitt or Burkitt-Like Leukaemia/Lymphoma (BL) Treated with an Adapted BFM Protocol <i>Blood</i> , 2006 , 108, 2438	3- 2 438	
46	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005 , 106, 3183-90	2.2	304
45	Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. <i>Blood</i> , 2005 , 105, 2869-76	2.2	82
44	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. <i>Blood</i> , 2005 , 106, 4315-21	2.2	279
43	t(14;22)(q32;q11) in non-Hodgkin lymphoma and myeloid leukaemia: molecular cytogenetic investigations. <i>British Journal of Haematology</i> , 2005 , 130, 845-51	4.5	8
42	G-banding and molecular cytogenetic analyses of marginal zone lymphoma. <i>British Journal of Haematology</i> , 2005 , 130, 890-901	4.5	24
41	Identification of a novel centrosome/microtubule-associated coiled-coil protein involved in cell-cycle progression and spindle organization. <i>Oncogene</i> , 2005 , 24, 1159-73	9.2	42

(2002-2005)

40	New probabilistic graphical models for genetic regulatory networks studies. <i>Journal of Biomedical Informatics</i> , 2005 , 38, 443-55	10.2	17
39	PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor. <i>Journal of Pathology</i> , 2005 , 206, 312-9	9.4	11
38	CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. <i>Cancer Research</i> , 2005 , 65, 2199-206	10.1	80
37	Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005 , 46, 693-701	1.9	45
36	Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs. <i>BMC Immunology</i> , 2004 , 5, 20	3.7	42
35	Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 1119-26	7.4	4
34	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004 , 103, 275-82	2.2	2955
33	Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma. <i>Journal of Molecular Diagnostics</i> , 2004 , 6, 297-307	5.1	37
32	Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. <i>New England Journal of Medicine</i> , 2004 , 351, 2159-69	59.2	1141
31	Characterization of a novel immunoglobulin-like domain containing receptor. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 323, 970-8	3.4	25
30	BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. <i>American Journal of Pathology</i> , 2004 , 165, 159-66	5.8	232
29	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. <i>Blood</i> ,	2.2	256
28	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work) <i>Blood</i> , 2004 , 104, 415-415	2.2	
27	Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. <i>Blood</i> ,	2.2	128
26	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003 , 3, 185-97	24.3	751
25	Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. <i>Journal of Experimental Medicine</i> , 2003 , 198, 851-62	16.6	869
24	Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. <i>American Journal of Pathology</i> , 2003 , 162, 681-9	5.8	34
23	Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study. <i>BMC Bioinformatics</i> , 2002 , 3, 36	3.6	84

22	The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. <i>American Journal of Surgical Pathology</i> , 2002 , 26, 1343-50	6.7	149
21	The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. <i>New England Journal of Medicine</i> , 2002 , 346, 1937-47	59.2	2971
20	Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. <i>Blood</i> , 2001 , 97, 1845-53	2.2	66
19	Binding of rabbit immunoglobulins to melanoma cells: a pitfall in the immunohistochemical study of malignant melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001 , 438, 421-3	5.1	2
18	The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. <i>American Journal of Pathology</i> , 2001 , 159, 1807-14	5.8	106
17	Marginal-Zone B Cells in the Human Lymph Node and Spleen Show Somatic Hypermutations and Display Clonal Expansion. <i>Blood</i> , 1999 , 93, 226-234	2.2	122
16	Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II. <i>British Journal of Haematology</i> , 1999 , 106, 1045-8	4.5	9
15	How reliable is histologic examination of bone marrow trephine biopsy specimens for the staging of non-Hodgkin lymphoma? A study of hairy cell leukemia and mantle cell lymphoma involvement of the bone marrow trephine specimen by histologic, immunohistochemical, and polymerase chain	1.9	35
14	Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes. <i>British Journal of Haematology</i> , 1998 , 102, 1307	1 -6 5	31
13	Molecular cloning of a gene on chromosome 19q12 coding for a novel intracellular protein: analysis of expression in human and mouse tissues and in human tumor cells, particularly Reed-Sternberg cells in Hodgkin disease. <i>Genomics</i> , 1998 , 54, 511-20	4.3	8
12	Primary low-grade B-cell lymphoma of MALT-type occurring in the liver: a study of two cases. Journal of Hepatology, 1997 , 27, 922-7	13.4	53
11	Concurrent lymphocyte predominance Hodgkin's disease and T-cell lymphoma. A report of three cases. <i>American Journal of Surgical Pathology</i> , 1996 , 20, 355-62	6.7	27
10	Lymphomatous polyposis. A neoplasm of either follicular mantle or germinal center cell origin. American Journal of Surgical Pathology, 1996 , 20, 442-52	6.7	49
9	The antigen-presenting cell function of Reed-Sternberg cells. <i>Leukemia and Lymphoma</i> , 1995 , 18, 35-40	1.9	21
8	Some desmoid tumors are characterized by trisomy 8. <i>Genes Chromosomes and Cancer</i> , 1994 , 10, 131-5	5	45
7	Distribution of mRNA coding for alpha-2-macroglobulin, the murinoglobulins, the alpha-2-macroglobulin receptor and the alpha-2-macroglobulin receptor associated protein during mouse embryogenesis and in adult tissues. <i>Differentiation</i> , 1994 , 55, 213-23	3.5	34
6	Restin in Hodgkin's disease and anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 1993 , 12, 21-6	51.9	7
5	T-cell lymphoma developing in Hodgkin's disease: evidence for two clones. <i>Journal of Pathology</i> , 1993 , 170, 239-48	9.4	22

LIST OF PUBLICATIONS

4	Translocation (11;14): a cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. <i>Journal of Pathology</i> , 1991 , 163, 13-8	9.4	101
3	Nuclear segmentation anomalies of neutrophils in neutrophilic dermatosis associated with myelodysplastic syndrome. <i>Journal of the American Academy of Dermatology</i> , 1991 , 24, 1037-8	4.5	1
2	Cytogenetic characterization of three cases of unusual B-cell non-Hodgkin's lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 1991 , 53, 229-35		2
1	Distribution of non-lymphoid, inflammatory cells in chronic HBV infection. <i>Journal of Pathology</i> , 1990 , 160, 223-30	9.4	27